“…Besides well-known mutations associated with HCC (e.g., TERT , TP53 , MYC , WNT , CTNNB1 , CCND1 , PTEN , [ 1 , 2 ]), numerous other mechanisms are deregulated and contribute to the development and heterogeneity of HCC, including DNA methylation events, chromatin structure changes, and post-transcriptional regulation of cancer-related factors by non-coding RNAs (e.g., microRNAs (miRNAs), long non-coding RNAs), or RNA-binding proteins [ 4 , 5 , 6 , 7 ]. Akin to genetic mutations, these non-genomic alterations can strongly affect the tumor microenvironment, the immune response, and the expression/activity of cancer-related factors (e.g., tumor suppressors or oncogenes), thereby markedly affecting disease development [ 1 , 8 ].…”